Boost Pharma

Based in Denmark, Boost Pharma develops innovative stem cell therapies aimed at treating Osteogenesis Imperfecta, a rare genetic bone disease characterized by fragile bones, enhancing patient outcomes with cutting-edge solutions. Founded in 2019 in Copenhagen S, Denmark, Boost Pharma is focused on developing therapies for Osteogenesis Imperfecta. The company successfully raised EUR 3. 1 million in funding in November 2025, led by Sound Bioventures, aimed at advancing clinical trials for their flagship product, BT-101, a novel cell therapy.

The firm has completed 1 deal to date. Lilian Walther Jallow, Cecilia Gotherstrom and Magnus Westgren co-founded the firm. Ingelise Saunders is leading the firm as CEO. BOOST Pharma specializes in developing innovative therapies for Osteogenesis Imperfecta (OI), a rare genetic bone disease characterized by fragile bones and frequent fractures.

The company's core product, BT-101, is a first-in-class cell therapy utilizing mesenchymal stem cells (MSCs) with high bone-forming capabilities. This therapy aims to address the root causes of OI by enhancing bone formation and reducing fracture rates, thereby improving the quality of life for affected children. BOOST Pharma's products primarily target pediatric patients diagnosed with OI, specifically those with Type III and IV forms of the disease. The company’s ongoing clinical development is focused on markets in the United States and Europe, where it intends to meet the growing demand for effective treatments for this underserved patient population.

BOOST Pharma's revenue generation model is centered around its clinical advancements and potential partnerships with healthcare institutions and research organizations. The firm may engage in transactions involving direct collaborations with hospitals and clinics for the administration of its therapies, particularly BT-101, distributed under a licensing or partnership framework. The company is expected to establish pricing structures that reflect the advanced nature of its products, aligning with the specialized treatment protocols necessary for managing OI. Additionally, as BOOST Pharma progresses through its clinical trials and gains regulatory approvals, it may enter into agreements with pharmaceutical distributors to broaden its market reach.

These collaborations will likely play a pivotal role in the commercialization of its therapies, facilitating access for healthcare providers and ultimately benefiting patients. In November 2025, Boost Pharma raised EUR 3. 1 million in venture funding led by Sound Bioventures. The company will utilize this funding to advance clinical trials of BT-101, its stem cell therapy for Osteogenesis Imperfecta, moving closer to regulatory approval and wider patient access.

Boost Pharma aims to expand its presence in the United States and European markets, focusing on increasing accessibility and treatment options for pediatric patients suffering from OI.